Experimental combo therapy for brain metastases shows early safety signals
NCT ID NCT05341349
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested whether adding a device that creates electric fields (NovoTTF-200M) to standard radiation and immunotherapy is safe for people with melanoma that has spread to the brain. Only one person took part before the study was stopped early. The main goal was to check for serious side effects in the brain and skin.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- New drug cocktail targets rare, aggressive melanoma